Serum Interleukin-33 Levels in Patients with Gastric Cancer

Abstract

Serum IL-33 may be a useful biomarker for predicting the prognosis of gastric cancer.

Correlations Between Serum IL33 and Tumor Development: a Meta-analysis

“…The survival time: In here, two papers (Sun et al, 2011;Hu et al, 2013). reported the correlation between IL33 expression level and survival time in tumors cases.…”

“…The correlation between IL-33 level and tumor stage: There were three researches (Sun et al, 2011;Bergis et al, 2013;Hu et al, 2013). described the correlation between IL33 level and tumor stage.…”

“…The meta-analysis results shown that the IL33 level in I-II stage is not higher than III-IV stage (P=0.29, 95%CI (-35.47, 10.65)). The correlation between IL33 expression level and tumor metastasis: There were two researches (Sun et al, 2011;Zhang et al, 2012). reported the correlation between IL33 level and tumor metastasis.…”

“…We first found 723 studies which met inclusion criteria, after reviewing carefully, all of the eight papers (Sun et al, 2011;Naumnik et al, 2012;Zhang et al, 2012;Bergis et al, 2013;Chen et al, 2013;Gangemi et al, 2013;Hu et al, 2013;Santulli et al, 2013). were included into this meta-analysis.…”

IL-33, an Important Biomarker in Non-small-cell Lung Cancer?

“…In addition, Fariadfar et al showed that IL-18 gene polymorphism contributes to the lung cancer risk, particularly among squamous carcinoma patients (Farjadfar et al, 2009). Interestingly, IL-33 levels in the serum of gastric cancer patients were significantly elevated in comparison with that of healthy volunteers, and higher serum levels of IL-33 in gastric cancer patients were found to correlate with several poor prognostic factors like depth of invasion, distant metastasis and advanced stage (stage III/IV) (Sun et al, 2011). On the contrary, no significant difference in IL-33 serum levels was found in hepatocellular carcinoma patients compared to liver cirrhosis patients and healthy controls (Bergis et al, 2013).…”